US OPEN: Wall Street opens higher despite weak payrolls data

• Senate approves Biden’s stimulus plan
• NFP below expectations
• Peloton (PTON.US) stock fell 7% despite upbeat earnings

US indices launched today's session higher, with the S&P 500 and the Nasdaq reaching new all-time highs, even despite slightly weaker NFP report which showed that US economy added 49K jobs in January, while analysts' expected 50k. December loss was revised much higher to 227K and manufacturing payrolls dropped by 10K, compared to forecasts of a 30K rise. Meanwhile, the Senate approved a budget plan that would allow for passage of President Joe Biden’s $1.9 trillion COVID-19 stimulus without Republican support. Also, financial regulators "believe the core infrastructure was resilient during high volatility and heavy trading volume" and the SEC and Commodity Futures Trading Commission are “reviewing whether trading practices are consistent with investor protection and fair and efficient markets”, the Treasury Department said following an analysis of recent retail frenzy.

US100  futures painted a fresh new ATH, however price quickly pulled back. If the current sentiment prevails, the attack on the support at 13,318 pts may be on the cards. This level is additionally strengthened by 50 SMA (green line). Source: xStation5.

Peloton (PTON.US) stock fell nearly 7% in the premarket despite the fact that the company posted quarterly earnings of 18 cents per share while analysts' expected earnings of 9 cents per share. Revenue also beat market forecasts. Fitness equipment maker’s will be incurring extra costs in the near term, however, to reduce shipping delays and is putting off the launch of a new treadmill while it focuses on cutting down on delivery times.

Peloton (PTON.US) stock launched today’s session lower and is testing lower limit of the triangle formation which coincides with 50 SMA (green line) and local support at $143.60. Should a break below this zone occur, downward move towards $109.49 may accelerate. Source: xStation5

Regeneron (REGN.US) stock rose nearly 4% after the company posted quarterly earnings of $9.53 a share, well above the consensus market expectations of $8.39 a share. Revenue came in  line with market estimates. The drugmaker results were helped by a nearly 10% increase in sales of its macular degeneration drug Eylea.

Ford (F.US) stock rose 2.3% in premarket after the company reported a quarterly profit of 34 cents per share, compared to analyst forecasts of a 7 cents per share loss. The automaker said an ongoing worldwide semiconductor shortage is cutting into production and profit.

Johnson & Johnson (JNJ.US) submitted its Covid-19 vaccine candidate for emergency use authorization by the Food and Drug Administration. If approved, it would become the third Covid-19 vaccine available to Americans, after the treatments from Pfizer and Moderna.